Prognostic Impact of Carcinoembryonic Angtigen (CEA) in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy
- 1 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 2 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 3 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 4 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- 5 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Abstract
Objective: To identify prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy (CCRT). Methods and Materials: We analyzed 76 patients with FIGO stage IB2 - IVb cervical cancer treated with CCRT between 2001 and 2006 at the Nagoya University Hospital. Patients with an advanced cervical cancer treated with CCRT. Overall survival (OS) and Progression-free survival (PFS) rates were estimated using the Kaplan-Meier method. The log-rank test was used to test differences in survival. Fisher's exact test was employed for univariate analysis. The Cox proportional hazard model was used for multivariate analysis. Results: The median age was 52, and the median follow-up period was 36 months. The 5 - year OS and PFS rates of all patients were 88.2 % and 72.4%, respectively. Twenty-one of the 76 patients were diagnosed with recurrence. A higher serum CEA before CCRT was an independent predictive factor for a poor prognosis on multivariate analysis. Conclusions: A high level of serum CEA was a predictive factor for a poor prognosis. New strategies should be considered to control disease in this group of patients.
- M. Parkin, F. Bray, J. Ferlay and P. Pisani, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 55, No. 2, 2005, pp. 74-108. doi:10.3322/canjclin.55.2.74
- L.-C. Horn, U. Fischer, G. Raptis, K. Bilek and B. Hentschel, “Tumor Size Is of Prognostic Value in Surgically Treated FIGO Stage II Cervical Cancer,” Gynecologic Oncology, Vol. 107, No. 2, 2007, pp. 310-315. doi:10.1016/j.ygyno.2007.06.026
- C. A. Perez, P. W. Grigsby, K. S. Chao, D. G. Mutch and M. A. Lockett, “Tumor Size, Irradiation Dose, and Long-Term Outcome of Carcinoma of Uterine Cervix,” International Journal of Radiation Oncology, Biology, Physics, Vol. 41, No. 2, 1998, pp. 307-317. doi:10.1016/S0360-3016(98)00067-4
- M. Morris, P. J. Eifel, J. Lu, et al., “Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1137-1143. doi:10.1056/NEJM199904153401501
- H. M. Keys, B. N. Bundy, F. B. Stehman, et al., “Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1154-1161. doi:10.1056/NEJM199904153401503
- P. G. Rose, B. N. Bundy, E. B. Watkins, et al., “Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer,” The New England Journal of Medicine, Vol. 340, No. 15, 1999, pp. 1144-1153. doi:10.1056/NEJM199904153401502
- W. A. Peters III, P. Y. Liu, R. Barrett, et al., “Concurrent Chemotherapy and Pelvic Radiation Therapy Compared with Pelvic Radiation Therapy Alone as Adjuvant Therapy after Radical Surgery in High-Risk Early-Stage Cancer of the Cervix,” Journal of Clinical Oncology, Vol. 18, No. 8, 2000, pp. 1606-1613. doi:10.1097/00006254-200008000-00017
- K. Shibata, F. Kikkawa, Y. Suzuki, et al., “Usefulness of Preoperative Chemoradiation in Locally Advanced Cervical Carcinoma,” Gynecologic and Obstetric Investigation, Vol. 57, No. 2, 2004, pp. 93-99. doi:10.1159/000075385
- C. W. Whitney, W. Sause, B. N. Bundy, et al., “A Randomized Comparison of Fluorouracil Plus Cisplatin versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix with Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study,” Journal of Clinical Oncology, Vol. 17, No. 5, 1999, pp. 1339-1348.